Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. ...
Jade Biosciences, Inc. (NASDAQ: JBIO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that emerged from a merger with Aerovate Therapeutics in 2024. The company is dedicated to developing transformative, disease-modifying therapies for autoimmune diseases, targeting significant unmet medical needs. Its lead candidate, JADE-001, is an anti-APRIL (A PRoliferation-Inducing ...Jade Biosciences, Inc. (NASDAQ: JBIO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that emerged from a merger with Aerovate Therapeutics in 2024. The company is dedicated to developing transformative, disease-modifying therapies for autoimmune diseases, targeting significant unmet medical needs. Its lead candidate, JADE-001, is an anti-APRIL (A PRoliferation-Inducing Ligand) antibody designed to treat immunoglobulin A (IgA) nephropathy, a serious kidney disease. Clinical trials for JADE-001 are expected to begin in the second half of 2025, with initial data anticipated in the first half of 2026. Beyond this, the pipeline includes two preclinical antibody programs, JADE-002 and JADE-003, expanding the company's reach in autoimmune indications.
Financially, Jade Biosciences launched with $80 million in funding, providing a solid runway for its development programs. As of the latest data, the company has a market capitalization of approximately $716 million, with a stock price around $22. The company holds significant cash reserves, with roughly $5.39 per share in cash, and a current ratio of 14.3, indicating strong liquidity. However, as a clinical-stage company with no product revenue, it is not yet profitable, reporting a net loss per share of $2.24 over the trailing twelve months. Research and development expenses are a primary cost driver, though specific figures are not provided in the data. The company's financial strategy focuses on funding clinical trials and advancing its pipeline, with a negative enterprise value-to-sales ratio reflecting the absence of revenue.
Key leadership includes CEO Tom Frohlich, a biotech and pharma veteran with over 20 years of experience, President of R&D Andrew King, and Chief Medical Officer Edward R. Conner. The team is dedicated to solving urgent challenges in autoimmune diseases, valuing rigor, ownership, and continuous improvement. With a focused pipeline, strong financial backing, and an experienced team, Jade Biosciences aims to establish itself as a leader in autoimmune therapeutics.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-127.4M
-83.0%
-26.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-94.9M
-33.3%
-81.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.2%
-60.1%
-37.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
20.33x
-2.9%
+4.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
